Verrica Pharmaceuticals Announces Participation in the 21st Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced participation of CEO Ted White in the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 3:00 p.m. ET. Investors can access a live webcast of the event through the provided link or on Verrica's website, with a replay available for 30 days post-event. The company focuses on developing treatments for dermatological conditions, including its leading candidate VP-102 for molluscum and warts, and VP-103 for plantar warts. Additionally, Verrica holds a licensing agreement with Lytix Biopharma for LTX-315.

Positive

• Verrica's CEO will present at a recognized healthcare conference, potentially increasing visibility.
• The company is developing multiple product candidates addressing significant unmet medical needs in dermatology.

Negative

• None.

WEST CHESTER, Pa., April 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will participate in a fireside chat at the 21^st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022 at 3:00 p.m. ET.

Participants may access a live webcast of the event through the following link: https://wsw.com/webcast/needham117/vrca/2246788.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

William Windham
Solebury Trout
646.378.2946
wwindham@soleburytrout.com

Terry Kohler
Chief Financial Officer
484.453.3296
info@verrica.com

Media:
Zara Lockshin
Solebury Trout
646.378.2960
zlockshin@soleburytrout.com

 

FAQ

When will Verrica Pharmaceuticals' CEO participate in the Needham Virtual Healthcare Conference?

Ted White, CEO of Verrica Pharmaceuticals, will participate on April 14, 2022, at 3:00 p.m. ET.

How can I access the webcast of the Needham Conference featuring Verrica Pharmaceuticals?

The live webcast can be accessed via the link provided in the press release or through the Investors/Presentations & Events section on Verrica's website.

What products is Verrica Pharmaceuticals currently developing?

Verrica is developing VP-102 for molluscum and warts, and VP-103 for plantar warts, as well as LTX-315 for dermatologic oncology.

What is the significance of VP-102 for Verrica Pharmaceuticals?

VP-102 addresses significant unmet needs in medical dermatology, targeting conditions like molluscum and common warts.